PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-<i>co...

Full description

Bibliographic Details
Main Authors: Kaining Zhi, Babatunde Raji, Anantha R. Nookala, Mohammad Moshahid Khan, Xuyen H. Nguyen, Swarna Sakshi, Tayebeh Pourmotabbed, Murali M. Yallapu, Harry Kochat, Erene Tadrous, Shelby Pernell, Santosh Kumar
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
poly(lactic-<i>co</i>-glycolic acid) (PLGA)
blood–brain barrier (BBB)
current Good Manufacturing Practice (cGMP)
Food and Drug Administration (FDA)
nanotechnology
Online Access:https://www.mdpi.com/1999-4923/13/4/500

Internet

https://www.mdpi.com/1999-4923/13/4/500

Similar Items